[Elsevier] Early health technology assessment of gene silencing therapies for lowering lipoprotein(a) in the secondary prevention of coronary heart disease |
|
This post will be closed automatically in 2026-07-01 18:38
Best Answer
Yesterday 18:39
|
| |
10
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
10
Ethical, legal, and regulatory perspectives in computational drug design
30
Drug Coated Balloon-based angioplasty for Chronic Total Occlusions: The PICCOLETO X study
10
Pulp and paper industry wastewaters and pollutants: characteristics, recovery, and utilization
10
Overview of pulp and paper industry
